REMSleep Holdings Announces Passing of Founder Thomas Wood and Appointment of Jeffrey Marshall as Chief Executive Officer
MWN-AI** Summary
REMSleep Holdings Inc. (OTCQB: RMSL), based in Blackshear, Georgia, announced significant leadership changes following the passing of founder Thomas Wood on February 26, 2026. Wood, a pioneering figure in sleep apnea treatment, dedicated his career to innovating better solutions for patients, with his most notable invention being the DeltaWave Nasal Pillow System. He held 26 patents and worked tirelessly to advance the company’s mission, transforming REMSleep into a key player in the medical device space focused on sleep-related disorders.
In the wake of Wood's death, the company appointed Jeffrey Marshall as the new Chief Executive Officer. Marshall, who has been with REMSleep as a strategy consultant since September 2025, brings a wealth of experience in sales, marketing, and business development, marking a seamless leadership transition. Anita Michaels, Wood’s sister and the company’s COO, has been elected as Chairman of the Board, ensuring a continuity of vision and deep understanding of the company’s goals and history.
This leadership shift comes as REMSleep has achieved crucial regulatory milestones, including FDA 510(k) clearance and Medicare reimbursement for the DeltaWave system. The board’s reconstitution, which includes the appointment of Alexander Johnson as a director, aims to fortify governance as the company embarks on launching its flagship product commercially.
Marshall expressed his commitment to driving sales and increasing brand awareness while acknowledging the foundation laid by Wood. The company envisions expanding its product portfolio in the long term, building on the technologies developed under Wood’s leadership. REMSleep is poised to further its mission of improving sleep apnea treatment and exploring innovations for chronic respiratory and neurological conditions, ensuring that Wood’s legacy continues.
MWN-AI** Analysis
REMSleep Holdings Inc. (OTCQB: RMSL) recently faced a significant milestone with the passing of founder Thomas Wood and the subsequent appointment of Jeffrey Marshall as CEO. Given this context, investors should consider both the inherent challenges and promising future that lie ahead for REMSleep.
The leadership transition appears to be well-planned; Thomas Wood had previously collaborated with Marshall and COO Anita Michaels to ensure operational continuity. The reconstituted Board, including industry experts like Alexander Johnson, indicates a focus on strong governance, which can be beneficial for stock stability and investor confidence. Under Marshall's guidance, the immediate priority is to capitalize on the commercial opportunity presented by the FDA-cleared DeltaWave Nasal Pillow System.
REMSleep's established regulatory milestones, including Medicare reimbursement approval, have positioned the company favorably within the sleep apnea market—a segment experiencing increasing awareness and demand due to rising incidences of sleep disorders. However, the company must now demonstrate its ability to translate these advancements into tangible sales and market penetration.
Investors should evaluate the potential for revenue generation in the near term, as Marshall’s experience in commercial strategy will be crucial in driving sales through partnerships with healthcare providers. The effective execution of marketing strategies will be critical in achieving brand awareness in a competitive landscape.
Additionally, the long-term vision surrounding a broader portfolio leveraging Woody's patented technologies opens avenues beyond sleep apnea, potentially enhancing growth prospects and shareholder value. While navigating this transitional phase, REMSleep must address market acceptance and maintain high standards of regulatory compliance.
In conclusion, while the company is in a transitional period, solid leadership and a promising product pipeline can create a favorable investment landscape for REMSleep Holdings. However, potential investors should remain aware of the inherent risks, including market competition and execution challenges.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Board of Directors Reconstituted With Anita Wood as Chairman; Company Positioned for Continued Growth and Commercialization
BLACKSHEAR, GEORGIA - March 4, 2026 (NEWMEDIAWIRE) - REMSleep Holdings Inc. (OTCQB: RMSL), a medical device company focused on innovative sleep apnea treatment solutions, today announced the passing of its founder, Thomas Wood, and the appointment of Jeffrey Marshall as Chief Executive Officer.
Thomas Wood, who founded REMSleep and served as Chairman of the Board and Chief Executive Officer, passed away on February 26, 2026. He dedicated his career to the relentless pursuit of better solutions for patients that suffer from sleep apnea. As an inventor and entrepreneur his design journey began in 1981 securing his first U.S. patent for the Nasal Air interface. He went on to be awarded 26 patents for various components of CPAP interfaces. Tom did not stop there; he remained resolute in his quest to design an even better interface with one goal in mind, to facilitate a full night's rest for patients with sleep apnea. This led to the formation of REMSleep Holdings Inc. and the development of DeltaWave Nasal Pillow System.
"Tom was more than a founder, he was a visionary and patient advocate who believed that sleep apnea patients deserved better options," said Anita Michaels, who has been elected Chairman of the Board. "He spent years raising funding to build DeltaWave, complete the FDA clearance process and built REMSleep from the ground up. His legacy lives on in the DeltaWave technology and in our commitment to bringing this innovation to the patients who need it."
Under Thomas Wood's leadership, REMSleep achieved significant regulatory and commercial milestones:
FDA 510(k) clearance for the DeltaWave Nasal Pillow System
PDAC coding approval enabling Medicare reimbursement
Buildout of manufacturing and distribution infrastructure
Positioning for commercial launch and market entry
Seamless Leadership Transition
What Tom understood, and planned for, was that building a company means building one that doesn’t depend entirely on any one person. Over the past several months, he worked alongside his sister Anita Michaels COO and incoming CEO Jeff Marshall to put the people, the systems, and the strategy in place for exactly this kind of transition.
Following Thomas Wood's passing, the Board of Directors has been reconstituted to ensure continuity and strong governance.:
- Anita Michaels has been elected Chairman of the Board. As Thomas Wood’s sister, COO, and now the company’s majority shareholder, Anita brings a deep understanding of REMSleep’s history, technology, and mission. She and Tom began collaborating in 1981, building a partnership that spanned more than four decades and developed into a shared vision for the company’s future. In April 2025, Anita became COO and worked closely with Tom to strengthen the company’s infrastructure, assemble the right team, and position REMSleep for the successful launch of the DeltaWave Nasal Pillow System in the U.S. market.
- Jeffrey Marshall has been appointed Chief Executive Officer and Director. Marshall brings extensive industry experience in sales, marketing, business development, and commercial strategy to lead REMSleep’s next phase of growth. He has served as a strategy consultant to REMSleep since September 2025 and has been a pivotal contributor to the company’s strategic plan.
- Alexander Johnson, Board Member, has been appointed as Director. Alexander has served as a strategic advisor to REMSleep and brings expertise in corporate restructuring, capital markets, and public company compliance.
"This transition is a pivotal moment for REMSleep," said Jeffrey Marshall, newly appointed CEO. "Tom built the foundation achieving FDA clearance, Medicare approval, and a differentiated product. Now it's our job to execute the commercial opportunity he created. The DeltaWave technology is ready for market, our infrastructure is in place, and we're focused on revenue generation and sustainable growth."
Marshall added, "I'm honored to carry forward Tom's vision. Our immediate priorities are straightforward: Drive sales through strategic sales and marketing plans that will gain brand awareness and bring DeltaWave to patients nationwide. We want to build partnerships with Durable Medical Equipment providers, physicians, sleep labs, and the entire sleep community."
This legacy plan, including Board of Director formation and CEO appointment, was in process prior to Tom’s passing.
Strong Foundation for Growth
The DeltaWave Nasal Pillow System is the flagship product that is now commercially available. It is the first product in what management envisions as a broader portfolio of solutions built on Tom’s patented technologies. REMSleep has a strategic roadmap that will enhance our future product portfolio.
Beyond sleep apnea, Tom’s original vision was aways broader. He believed that the same engineering principles that made the DeltaWave effective for sleep apnea patients could be applied to help patients battling other chronic respiratory and neurological diseases. That vision is now part of the Company’s strategic roadmap.
"Tom's passing is a profound loss, but his work is far from finished," said Anita Michaels. "We have a responsibility to our shareholders, to sleep apnea patients, and to Tom's memory to see this through. With Jeff's leadership and our reconstituted Board, REMSleep is well-positioned to deliver on the promise of the DeltaWave technology and develop the pipeline of products Tom envisioned."
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, but are not limited to, statements regarding the Company's plans for commercialization, revenue generation, capital raising, and business development. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's ability to raise capital, market acceptance of the Company's products, competitive factors, regulatory developments, and general economic conditions. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
About REMSleep Holdings Inc.
REMSleep Holdings Inc. (OTCQB: RMSL) is a medical device company focused on innovative sleep apnea treatment solutions. The Company's DeltaWave Nasal Pillow System has received FDA 510(k) clearance and PDAC coding approval for Medicare reimbursement. REMSleep is committed to improving outcomes for patients with sleep apnea through differentiated technology and patient-centered design. For more information, visit www.REMSleep.com.
Contact
Jeff Marshall, Chief Executive Officer
REMSleep Holdings, Inc.
(912) 590-2001
jmarshall@remsleep.com
www.remsleep.com
FAQ**
How does the reconstitution of the Board of Directors, particularly with Anita Michaels as Chairman, position REMSleep Holdings Inc. (OTCQB: RMSL) for future growth and commercialization following the passing of its founder?
What specific strategies does Jeffrey Marshall, the new CEO of REMSleep Holdings Inc. (OTCQB: RMSL), plan to implement to drive sales and brand awareness for the DeltaWave Nasal Pillow System in the competitive medical device market?
Given the strategic roadmap for REMSleep Holdings Inc. (OTCQB: RMSL), how does the company plan to leverage Tom Wood's legacy and patented technologies to expand beyond sleep apnea into other chronic respiratory and neurological conditions?
What is the anticipated timeline for the commercial launch of the DeltaWave Nasal Pillow System, and how have the recent leadership changes at REMSleep Holdings Inc. (OTCQB: RMSL) influenced this timeline and overall market entry strategy?
**MWN-AI FAQ is based on asking OpenAI questions about REMSleep Holdings Inc (OTC: RMSL).
NASDAQ: RMSL
RMSL Trading
-6.15% G/L:
$0.0061 Last:
1,101,050 Volume:
$0.0065 Open:
